Contrasting Alvotech (NASDAQ:ALVO) & Valion Bio, Inc. Common Stock (NASDAQ:VBIO)

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Alvotech (NASDAQ:ALVO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends.

Valuation and Earnings

This table compares Valion Bio, Inc. Common Stock and Alvotech”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780,000.00	1.07	-$8.88 million	($159.25)	-0.01
Alvotech	$588.90 million	2.35	$27.92 million	($0.61)	-7.51

Alvotech has higher revenue and earnings than Valion Bio, Inc. Common Stock. Alvotech is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Comparatively, 0.5% of Alvotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Valion Bio, Inc. Common Stock and Alvotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%
Alvotech	-36.31%	N/A	-11.73%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Valion Bio, Inc. Common Stock and Alvotech, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1	0	0	0	1.00
Alvotech	2	1	4	0	2.29

Alvotech has a consensus price target of $8.50, suggesting a potential upside of 85.59%. Given Alvotech’s stronger consensus rating and higher possible upside, analysts plainly believe Alvotech is more favorable than Valion Bio, Inc. Common Stock.

Risk & Volatility

Valion Bio, Inc. Common Stock has a beta of 1.8, suggesting that its stock price is 80% more volatile than the S&P 500. Comparatively, Alvotech has a beta of 0.2, suggesting that its stock price is 80% less volatile than the S&P 500.

Summary

Alvotech beats Valion Bio, Inc. Common Stock on 9 of the 13 factors compared between the two stocks.

About Valion Bio, Inc. Common Stock

Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.